Welcome, visitor! [ Login

Dragon Signs International Marketing and Licensing Agreement

News

Dragon Pharmaceuticals Inc. is pleased to announce that it has entered into a marketing and licensing agreement with Jelfa S.A. of Poland for the distribution of Erythropoietin (EPO), a blood growth protein used to treat anemia, in Central and Eastern Europe and the Commonwealth of Independent States (“CIS”).

The agreement grants Jelfa, the second largest pharmaceutical company in Poland, an exclusive license to sell Dragon’s EPO across 23 countries in Central and Eastern Europe and the CIS. Jelfa will also be responsible for obtaining all product registration and marketing approvals from the appropriate regulatory authorities.

The regulatory dossier for Dragon’s EPO will be submitted initially to the Polish regulatory authorities for marketing approval. Regulatory submissions will be filed in the remaining territories subsequent to receipt of approval in Poland. Dragon and Jelfa management anticipate that the regulatory submission to Polish authorities will be filed during May 2001 and that product sales in Poland will commence in early 2002.

Dragon’s proprietary protein expression technology produces substantially higher yields of EPO with a lower cost per dose than that of the world’s leading EPO manufacturers. Dragon and Jelfa management anticipate that the significantly lower price of Dragon’s product will provide a commanding competitive advantage in the territories covered by this agreement.

According to audited IMS Health Data figures, the 1999 world market for EPO was US$4.3 billion, 80% of which was based on sales to North America and the European Union. Market penetration of EPO in countries outside North America and the European Union has been severely limited because of the high cost of currently available product. Dragon expects that the introduction of affordably priced EPO will stimulate a substantial increase in the volume of EPO consumed by these highly price conscious markets.

About Dragon Pharmaceuticals Inc.

Dragon Pharmaceuticals is an international biopharmaceutical corporation engaged in the development and commercialization of generic as well as novel and patentable therapeutics. Based on its proprietary protein expression technology, Dragon has become one of the world’s lowest cost producers of Erythropoietin (EPO), and is in the process of applying its platform technology to a pipeline of additional products.

Legal Dragon Pharma

Discount pharmacy supplier of Dragon Pharma: Enantat 250 for Sale.

No Tags

12 total views, 1 today

  

  • Dragon Pharma Sells Polymun Development

    Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) (“the Company”) announced today that the Company has sold its Development and Manufacturing Agreement with Polymun Scientific Immunbiologische Forschung GmBh (“Polymun”) to AS Biotech AG, a Swiss company, for US$1 million. Prior to the acquisition of Oriental Wave Holding Limited in early 2005, Dragon entered into a […]

  • Dragon Announces Growth in International EPO Sales

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced the receipt of EPO sales orders from international markets outside of China totaling $937,500 in the first quarter of 2002, representing a 113% increase over total year international sales of $440,125 in 2001. To date, the Company has completed EPO shipments for $847,500 of first quarter orders, […]

  • Dragon Ships EPO Internationally

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]

  • Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

    Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]

  • Dragon Announces Participation at Biopartnering Europe 2001

    Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]

Dragon Pharma Suppliers

dragon pharma source
american steroids online
real dragon pharma supplier
dragon pharma for sale
dragon pharma legit supplier
buy dragon pharma
dragon pharma store
buy steroids
dragon pharma legit dragon pharma anabolics